Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cidara Thera (NQ: CDTX )

0.6155 -0.0545 (-8.13%)
Streaming Delayed Price Updated: 12:51 PM EDT, Aug 9, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cidara Thera

< Previous 1 2 Next >
Short Volatility Alert: Cidara Therapeutics, Inc.
On Thursday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went down -3.74% to $0.72. The overall sentiment for CDTX has... 
Via Benzinga
Short Volatility Alert: Cidara Therapeutics, Inc.
On Friday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went up +7.53% to $0.785. The overall sentiment for CDTX has been... 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Cidara Pursues FDA Approval For Bloodstream Infections Candidate
Cidara Therapeutics, Inc. (NASDAQ: CDTX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead asset Rrezafungin for the treatment of candidemia and... 
Via Benzinga
With FDA Submission, Cidara Therapeutics Inks US Pact For Bloodstream Infection Candidate
 
Via Benzinga
Recap: Cidara Therapeutics Q1 Earnings
Cidara Therapeutics (NASDAQ:CDTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
From Cidara Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 9.4% to $0.81 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million. 
Via Benzinga
83 Biggest Movers From Yesterday
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows. 
Via Benzinga
Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. 
Via Benzinga
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for another dive into the market this morning with a look at the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market value of their outstanding shares is at $18.4... 
Via Benzinga
Cidara Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, Cidara Therapeutics (NASDAQ:CDTX) posted sales of $7.22 million. Earnings were up 7.08%, but Cidara Therapeutics still reported an... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Eargo (NASDAQ:EAR) shares rose 10.... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 102.3% to $0.69 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.3... 
Via Benzinga
FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza
The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX)... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.